Tags : Cancer Genetics

Cancer Genetics Announces Acquisition of NovellusDx to Expand its Oncology

Shots: Cancer Genetics is acquiring NovellusDx by paying equity of ~49% in Cancer Genetics. NovellusDx will also provide $2. 3M bridge loan to Cancer Genetics Cancer Genetics will get hold of NovellusDx’s technology and machine learning capabilities for development of oncology drugs The acquisition will strengthen the focus on oncology precision medicines, and developing targeted […]Read More